-
1872 年Perls [1]首次报道了恶性肿瘤的眼内转移,并一度被认为是眼内的罕见病症。之后陆续有类似报道,目前已经认为眼内转移瘤是成人最常见的眼内恶性肿瘤,经常是肿瘤扩散的迹象[2]。近年来,随着肿瘤发病率的升高、癌症患者寿命的延长、诊断技术的不断改进,其发病率呈逐渐升高的趋势[3]。尽管眼科影像学检查(如彩色多普勒超声、眼底血管造影、增强CT及MRI等)都能用于临床对眼内转移瘤的诊断,但无论哪种检查都有一定的局限性,不一定能准确诊断。有时即使可以明确眼部病变的良恶性,但对于确定原发、继发或转移性恶性肿瘤,是否同时存在全身其他部位的病变及疾病的分期不能完全显示。研究证实8%~30%的病例中转移瘤的诊断先于系统性肿瘤,而且进行一般筛查之后仍有51%的患者没有找到原发病灶[3]。18F-FDG PET/CT为一次性检查,全身成像,既可以将眼内病变从形态(CT)到功能(PET)进行诊断,又可以发现有无其他脏器的转移及原发灶。因此,我们对行18F-FDG PET/CT检查的53例眼内转移瘤患者进行回顾性分析,总结眼内转移瘤的18F-FDG PET/CT影像学特点及应用价值,为临床诊断、分期和制定合理的治疗方案提供帮助。
18F-FDG PET/CT在拟诊眼内转移瘤患者中的应用价值
Value of 18F-FDG PET/CT in patients with suspected intraocular metastases
-
摘要:
目的 探讨眼内转移瘤18F-FDG PET/CT的影像学特点及临床应用价值。 方法 回顾性分析2011年3月至2019年2月于北京医院和首都医科大学附属北京同仁医院经病理学或临床确诊的眼内转移瘤患者53例(54只眼睛,其中1例为双眼转移),其中男性23例、女性30例,年龄22~73(52.7±11.6)岁。所有患者行18F-FDG PET/CT检查,并对影像学表现特征及参数进行分析,包括最大标准化摄取值(SUVmax)和平均标准化摄取值(SUVmean);评估PET/CT对肿瘤原发灶的探查及其他部位转移灶发现的价值。多组计量资料之间的比较采用方差分析;相关性采用Pearson相关分析。 结果 眼内转移瘤CT形态多样,以梭形软组织影最为多见。47例可测量的眼内转移瘤CT值与SUVmax、SUVmean均无明显线性关系(均r=−0.252,均P=0.088)。50例放射性摄取增高转移瘤的SUVmax、SUVmean均与其长径、短径、上下径呈显著正相关(r=0.631~0.791,均P=0.000)。既往无肿瘤病史患者43例,PET/CT对原发灶的检出率为97.7%(42/43),其中来源于肺癌36例、乳腺癌2例、食管癌、胃癌、鼻咽癌和前列腺癌各1例。PET/CT显示转移灶≥2个的患者51例(51/53,96.2%),其中主要伴淋巴结转移43例(43/53,81.1%)、骨转移42例(42/53,79.2%)。 结论 眼内转移瘤CT形态多样,SUV仅与其大小有关。18F-FDG PET/CT在眼内转移瘤诊断、肿瘤原发灶的探查及其他部位转移灶的发现等方面具有重要的临床应用价值。 -
关键词:
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 眼内转移瘤
Abstract:Objective To analyze the features and application value of 18F-FDG PET/CT in detecting intraocular metastases. Methods A total of 53 patients with intraocular metastasis (54 eyes, including 1 case of binocular metastasis) diagnosed by pathology or clinical assessment at the Beijing Hospital and Beijing Tongren Hospital, Capital Medical University from March 2011 to February 2019 were enrolled in this retrospective study. The patients included 23 males and 30 females aged 22–73(52.7±11.6) years. All patients underwent 18F-FDG PET/CT, and the features and parameters of the resulting images, including maximum (SUVmax) and average (SUVmean) standardized uptakes, were analyzed. The value of PET/CT for the detection of primary tumors and metastases was then assessed. Analysis of variance was used to compare the data of multiple groups, and Pearson's correlation analysis was used to determine correlations. Results Intraocular metastases showed a variety of unique CT features, the most common of which was spindle-like soft tissue shadows. No significant linear relationship between the CT value and SUVmax or SUVmean (both r=−0.252; both P=0.088) among 47 cases of measurable intraocular metastasis was detected. SUVmax and SUVmean were positively correlated with their long, short, upper, and lower diameters (r=0.631–0.791; all P=0.000). The detection rate of the primary focus by PET/CT among 43 patients with no prior history of cancer was 97.7% (42/43). Among the cases of intraocular metastasis, 36 originated from lung cancer, 2 were from breast cancer, 1 was from esophageal cancer, 1 was from gastric cancer, 1 was from nasopharyngeal cancer, and 1 was from prostate cancer. PET/CT revealed 51 patients (51/53, 96.2%) with more than two metastatic lesions, 81.1% (43/53) with lymph node metastasis, and 79.2% (42/53) with bone metastasis. However, PET/CT may result in false negative findings for small intraocular and brain metastases. Conclusions Intraocular metastases exhibit a variety of distinct CT features, and only the SUV is related to the tumor size. 18F-FDG PET/CT is useful for the diagnosis of intraocular metastases, exploration of primary tumors, and discovery of metastases in other sites. -
-
[1] Perls M. Beiträge zur Geschwulstlehre[J]. Archiv Pathol Anat, 1872, 56(4): 437−467. DOI: 10.1007/BF01973432. [2] Konstantinidis L, Damato B. Intraocular Metastases—A Review[J/OL]. Asia Pac J Ophthalmol, 2017, 6(2): 208−214[2019-03-31]. https://journals.lww.com/apjoo/Fulltext/2017/03000/Intraocular_Metastases_A_Review.12.aspx. DOI: 10.22608/APO.201712. [3] Mathis T, Jardel P, Loria O, et al. New concepts in the diagnosis and management of choroidal metastases[J]. Prog Retin Eye Res, 2019, 68: 144−176. DOI: 10.1016/j.preteyeres.2018.09.003. [4] Bornfeld N, Biewald E, Bauer S, et al. The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors[J/OL]. Dtsch Arztebl Int, 2018, 115(7): 106−111[2019-03-31]. https://www.aerzteblatt.de/int/archive/article/196273. DOI: 10.3238/arztebl.2018.0106. [5] Arepalli S, Kaliki S, Shields CL. Choroidal metastases: Origin, features, and therapy[J]. Indian J Ophthalmol, 2015, 63(2): 122−127. DOI: 10.4103/0301−4738.154380. [6] 丛春霞, 林锦镛, 王兰惠. 葡萄膜转移癌的临床病理学观察[J]. 中华眼科杂志, 2016, 52(10): 769−774. DOI: 10.3760/cma.j.issn.0412−4081.2016.010.010.
Cong CX, Lin JY, Wang LH. Clinical and pathologic observation of uveal metastatic carcinoma[J]. Chin J Ophthalmol, 2016, 52(10): 769−774. DOI: 10.3760/cma.j.issn.0412−4081.2016.010.010.[7] 郑惠, 董东升. 脉络膜转移癌的临床诊断及鉴别分析[J]. 现代肿瘤医学, 2016, 24(20): 3202−3205. DOI: 10.3969/j.issn.1672−4992.2016.20.008.
Zheng H, Dong DS. Clinical diagnosis and identification of metastatic tumor of the choroid[J]. J Med Oncol, 2016, 24(20): 3202−3205. DOI: 10.3969/j.issn.1672−4992.2016.20.008.[8] Papastefanou VP, Islam S, Szyszko T, et al. Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors[J]. Br J Ophthalmol, 2014, 98(12): 1659−1665. DOI: 10.1136/bjophthalmol−2014−305304. [9] Hübnr KF, Buonocore E, Gould HR, et al. Differentiating Benign from Malignant Lung Lesions Using "Quantitative" Parameters of FDG PET Images[J]. Clin Nucl Med, 1996, 21(12): 941−949. DOI: 10.1097/00003072−199612000−00005. [10] 葛冉, 赵丽霞, 田蓉, 等. <sup>18</sup>F-FDG PET-CT在寻找转移瘤原发灶中的临床价值[J]. 中国临床医学影像杂志, 2012, 23(10): 722−726. DOI: 10.3969/j.issn.1008−1062.2012.10.011.
Ge R, Zhao LX, Tian R, et al. The role of <sup>18</sup>F-FDG PET-CT in the detection of primary lesions for patients with tumor metastasis[J]. J Chin Clin Med Imaging, 2012, 23(10): 722−726. DOI: 10.3969/j.issn.1008−1062.2012.10.011.[11] Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis[J]. Eur Radiol, 2009, 19(3): 731−744. DOI: 10.1007/s00330−008−1194−4. [12] Patel P, Finger PT. Whole-Body <sup>18</sup>F FDG Positron Emission Tomography/Computed Tomography Evaluation of Patients With Uveal Metastasis[J]. Am J Ophthalmol, 2012, 153(4): 661−668. DOI: 10.1016/j.ajo.2011.09.028. [13] 张毓艺, 姚稚明, 陈聪霞, 等. FDG PET/CT原发性代谢对非小细胞肺癌区域淋巴结转移预测价值[J]. 中华肿瘤防治杂志, 2018, 25(11): 816−820. DOI: 10.16073/j.cnki.cjcpt.2018.11.013.
Zhang YY, Yao ZM, Chen CX, et al. Value of metabolism by using FDG PET/CT of NSCLC primary tumor in prediction of lymph node metastasis[J]. Chin J Cancer Prev Treat, 2018, 25(11): 816−820. DOI: 10.16073/j.cnki.cjcpt.2018.11.013.[14] Orsaria P, Chiaravalloti A, Caredda E, et al. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer[J]. Anticancer Res, 2018, 38(12): 6639−6652. DOI: 10.21873/anticanres.13031. [15] Ho KC, Toh CH, Li SH, et al. Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases[J]. Eur J Nucl Med Mol Imaging, 2019, 46(2): 467−477. DOI: 10.1007/s00259−018−4210−1.